Post Profile

AstraZeneca rebuilds cancer drug hopes with new lung data

MADRID (Reuters) - Two AstraZeneca drugs tackling lung cancer in different ways delivered encouraging results on Saturday, helping the British group offset July's big clinical trial setback in the disease.
read more


Related Posts

AstraZeneca third-line lung cancer trial delayed by few months

Health : Reuters: Health

LONDON (Reuters) - A clinical study testing AstraZeneca's experimental immunotherapy drugs in lung cancer patients who have already received at least two previous treatments will take longer than initially expected to produce result...

Roche eye drug fails late-stage trial in blow to pipeline

Health : Reuters: Health

ZURICH (Reuters) - A drug Roche had hoped would prevent loss of vision and become a big seller failed a late-stage trial, leading some analysts to say on Friday it now had no future.

AstraZeneca ovarian cancer drug slows disease markedly in study

Health : Reuters: Health

LONDON (Reuters) - AstraZeneca's ovarian cancer drug Lynparza slowed disease progression sharply in a closely watched clinical trial, boosting hopes for a product that belongs to a novel drug class called PARP inhibitors.

AstraZeneca lung cancer study fails in big setback for company

Health : Reuters: Health

LONDON (Reuters) - AstraZeneca's combination of two immunotherapy drugs, durvalumab and tremelimumab, failed to help patients as hoped in a closely watched advanced lung cancer trial, the British company said on Thursday.

AstraZeneca aims to offset drug setback at big cancer congress

Health : Reuters: Health

LONDON (Reuters) - After last month's big clinical trial setback in lung cancer, AstraZeneca will seek to rebuild its oncology reputation next week when it unveils full details of two key clinical trials tackling the disease in diff...


Copyright © 2016 Regator, LLC